Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Eur J Clin Nutr ; 59(4): 480-8, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15674310

RESUMO

BACKGROUND: Hyperhomocysteinemia (HHCY) is a risk factor for cardiovascular diseases (CVD). HHCY may interact with hypertension (HTEN) and an unfavorable cholesterol profile (UNFAVCHOL) to alter the risk of CVD. OBJECTIVES: To estimate the prevalences of HHCY (1) isolated and (2) in combination with UNFAVCHOL and/or HTEN in different age categories. To provide information that may improve the screening and treatment of subjects at risk of CVD. DESIGN: Cross-sectional data on 12,541 men and 12,948 women aged 20 + y were used from nine European studies. RESULTS: The prevalence of isolated HHCY was 8.5% in subjects aged 20-40 y, 4.7% in subjects aged 40-60 y and 5.9% in subjects aged over 60 y. When combining all age groups, 5.3% had isolated HHCY and an additional 5.6% had HHCY in combination with HTEN and/or UNFAVCHOL. The combinations of risk factors increased with age and, except for HHCY&UNFAVCHOL, were more prevalent than predicted by chance. Of the young subjects (20-40 y), 24% suffered from one or more of the investigated CVD risk factors. This figure was 75.1% in the old subjects (60+ years). CONCLUSIONS: A substantial number of subjects in selected European populations have HHCY (10.9%). In half of these cases, subjects suffer also from other CVD risk factors like UNFAVCHOL and HTEN. Older people in particular tend to have more than one risk factor. Healthcare professionals should be aware of this when screening and treating older people not only for the conventional CVD risk factors like UNFAVCHOL and HTEN but also HHCY, as this can easily be reduced through increased intake of folic acid via supplement or foods fortified with folic acid.


Assuntos
Doenças Cardiovasculares/sangue , Hipercolesterolemia/epidemiologia , Hiper-Homocisteinemia/epidemiologia , Hipertensão/epidemiologia , Adulto , Fatores Etários , Pressão Sanguínea/fisiologia , Colesterol/sangue , Estudos Transversais , Europa (Continente)/epidemiologia , Feminino , Homocisteína/sangue , Humanos , Hipercolesterolemia/sangue , Hiper-Homocisteinemia/sangue , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Fatores Sexuais
3.
Cardiovasc Surg ; 10(1): 45-8, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11790575

RESUMO

Recently a new identified genetic variant in the 3'-untranslated region of the prothrombin gene (G20210A allele) associated with increased plasma prothrombin levels has been linked to an increased risk of venous thromboembolism (VTE). To determine the importance of this G20210A allele as a causative risk factor for VTE in the general population, we analysed the data of an epidemiologic investigation on thrombophilia in young people, the Oporto Thrombophilia Study (PORtromb). Forty cases (mean age: 27 yr old) with a first episode of VTE under 40 yr old, and 100 healthy subjects, were evaluated. Heterozygosity for the G20210A allele was present in 12.5% of VTE cases and in 5% of controls, indicating a possible marginal increase of VTE risk in carriers of the allele (odds ratio: 2.71: 95% CI 0.74-9.95).


Assuntos
Mutação Puntual , Protrombina/genética , Trombose Venosa/sangue , Trombose Venosa/genética , Regiões 3' não Traduzidas , Adolescente , Adulto , Alelos , Intervalos de Confiança , Feminino , Frequência do Gene/genética , Heterozigoto , Humanos , Masculino , Portugal/epidemiologia , Prevalência , Fatores de Risco , Trombofilia/sangue , Trombofilia/complicações , Trombofilia/genética , Trombose Venosa/complicações
4.
Immunohematology ; 18(3): 59-64, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-15373552

RESUMO

The most clinically important blood group systems in transfusion medicine, excluding the ABO system, are the RH, Kell, and Kidd systems. Alloantibodies to antigens of these systems may be produced following blood transfusion or during pregnancy and can result in serious hemolytic transfusion reactions and hemolytic disease of the newborn. We developed rapid and robust techniques for RHD, RHCE, KEL, and JK genotyping with the use of a real-time polymerase chain reaction instrument. Two fluorescence-based methods for the detection of amplification products were used: for KEL1/KEL2, JK1/JK2, and RHE/RHe (exon 5) we used the hybridization probes protocol; for RHC/RHc the analysis was done in sequences of exon 1 for RHC and exon 2 for RHc; and for RHD, analysis was done in sequences of intron 4, exon 7, and exon 4 pseudogene using the SYBR Green I protocol. The genotyping tests were validated with samples from 85 Caucasian Portuguese and 15 Black European blood donors. Complete phenotype-genotype correlations were obtained. The potential use of the presented methods can be predicted in clinical transfusion medicine, allowing appropriate monitoring, early intervention, and improved care. When blood group genotyping techniques are necessary, this methodology is highly competitive for a routine laboratory.

6.
Immunohematology ; 17(2): 42-4, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-15373590

RESUMO

The Duffy blood group system has clinical importance due to involvement in transfusion reactions and hemolytic disease of the newborn. Recently, the molecular basis of the two alleles, FY*A and FY*B (125G>A), and the mutation situated in the promoter region of the FY gene (-33T>C), have been elucidated. In order to develop an accurate, easy, and rapid genotyping method, we describe a procedure using the LightCycler. Samples from 53 Caucasian Portuguese blood donors and 7 black, healthy, European individuals were phenotyped with commercial antisera. DNA was extracted from blood samples and the relevant sequences were amplified with the same cycling conditions, using real-time polymerase chain reaction. The melting point of the FY*A allele was 63 degrees C and of the FY*B allele, 55 degrees C. The allele without mutation at the promoter region had a melting point at 64 degrees C and the FY*B silent allele at 58 degrees C. The results in Caucasian individuals were similar to those found in European and American populations. When FY genotyping techniques are necessary, the methodology described is preferable to conventional methods as it is reliable, high speed, and uses small volumes, providing a highly competitive technology for use by a routine laboratory.

11.
Haemostasis ; 29(4): 212-8, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10702702

RESUMO

OBJECTIVE: We investigate whether each of the following: HPA-1, Factor V Leiden, prothrombin gene variant and the methylene tetrahydrofolate reductase gene (MTHFR) mutation, are risk factors for acute coronary disease in Portuguese patients. MATERIAL AND METHODS: 100 blood donors and 52 patients with an established diagnosis of myocardial infarction or unstable angina were evaluated for genetic risk factors, by determining HPA-1 genotype, Factor V Leiden, Prothrombin 20210 variant and MTHFR mutation. RESULTS: We found a prevalence of 2.0% for Factor V Leiden, 5.0% for the Prothrombin 20210 variant and 66% for the MTHFR mutation in blood donors. These values are similar to those found in the patients (1.9, 3.8 and 58%, respectively). We found that 28/100 controls had the PI(A2) polymorphism, a frequency statistically different from that in the patients (23/52). This difference was even more pronounced in patients less than 60 years old (27/96 vs. 13/24). CONCLUSION: Factor V Leiden, Prothrombin 20210 variant and MTHFR mutation do not seem to represent risk factors for acute coronary disease. However, the PI(A2) polymorphism could have a role in the pathogenesis of this disease. The presence of multiple genetic factors, more than single ones, could influence the development and outcome of myocardial infarction and unstable angina. Larger studies are needed in order to have a better insight into the pathophysiological mechanisms of this disease, along with its prevention and the development of new treatments.


Assuntos
Doença das Coronárias/genética , Resistência à Proteína C Ativada/genética , Doença Aguda , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Angina Instável/sangue , Angina Instável/epidemiologia , Angina Instável/genética , Antígenos de Plaquetas Humanas/genética , Doença das Coronárias/sangue , Doença das Coronárias/epidemiologia , Fator V/genética , Feminino , Frequência do Gene , Variação Genética , Heterozigoto , Homozigoto , Humanos , Masculino , Metilenotetra-Hidrofolato Redutase (NADPH2) , Pessoa de Meia-Idade , Infarto do Miocárdio/sangue , Infarto do Miocárdio/epidemiologia , Infarto do Miocárdio/genética , Oxirredutases atuantes sobre Doadores de Grupo CH-NH/genética , Mutação Puntual , Polimorfismo Genético , Portugal/epidemiologia , Protrombina/genética , Fatores de Risco
12.
Transfus Sci ; 19(2): 119-20, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10187036

RESUMO

HGV can be transmitted by transfusion and is capable of inducing persistent infection. Thus far it appears to have no discernable disease association. We determined the infection rate of HGV in volunteer blood donors and patient with risk factors for viral transmission through the blood. The association between HGV infection and exposure to labile blood products could be a problem for blood banks in the future.


Assuntos
Bancos de Sangue/normas , Flaviviridae , Hepatite Viral Humana/transmissão , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...